| INTELLIA THERAPEUTICS |
| USA |
| Gesundheit |
| US45826J1051 / A2AG6H |
| 38I (Frankfurt) / NTLA (NASDAQ) |
| FRA:38I, ETR:38I, 38I:GR, NASDAQ:NTLA |
| - |
| https://www.intelliatx.co.. |
|
Intellia Therapeutics is a clinical-stage genome editing company focused on developing curative treatments using CRISPR/Cas9 technology. The company transforms medicine by permanently editing and correcting disease-associated genes within the human b..
>Volltext.. |
| 1599.44 Mio. EUR |
| 1296.84 Mio. EUR |
| 57.73 Mio. EUR |
| -357.07 Mio. EUR |
| -352.08 Mio. EUR |
| -3.26 EUR |
| 79.62 Mio. EUR |
| 132.63 Mio. EUR |
| -336.76 Mio. EUR |
| 4.33 |
| 3.06% |
| 29.92% |
| - |
| - |
| - |
| - |
| INTELLIA |
| 24.04.26 |